ARS Pharmaceuticals, Inc. SPRY Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Revenue Under Collaboration Agreements | $12M+23.5% | $9.72M-88.2% | $82.39M-1.7% | $83.83M+2.6% | $81.74M+0.3% | |
| Revenue Under Supply Agreements | $5.11M+116% | $2.37M+29.2% | $1.83M+167% | $688K+88.5% | $365K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ARS Pharmaceuticals, Inc. break its business down?
- ARS Pharmaceuticals, Inc. (SPRY) reports revenue by product across 2 parts — Revenue Under Collaboration Agreements and Revenue Under Supply Agreements. Each is extracted from the segment footnotes and tracked over time.
- Where does ARS Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ARS Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
